Marketing Analysis of the Assortment of Drugs for the Treatment of Herpes Viral Diseases at the Pharmaceutical Market of Ukraine

Abstract

Nowadays there is a tendency towards the spread of viral diseases that cause significant complications to human health. Therefore, the question of creating new drugs that have a high antiviral effect is topical. The aim. To study the range of drugs in Ukraine for the treatment of herpes viral diseases. Materials and methods. In the work were used the list of drugs from official sources of information, which were processed by methods of generalization, systematization, graphic, comparative and structural analysis. Results and discussion. The marketing research of drugs for the treatment of herpes viral diseases presented at the pharmaceutical market of Ukraine has been conducted. According to the results it is found that 80 drugs for the treatment of herpes viral diseases of various dosage forms are presented in the domestic market, of which 70 % – tablets; 51 % – medicines produced by the industry of Ukraine; 94 % – are monocomponent preparations. Soft drugs play important role in the treatment of skin diseases because they provide a direct effect of the drugs on the pathogens, eliminate inflammatory phenomena and eliminate or reduce the symptoms of the disease. Soft dosage drugs have practically no contraindications, they can be used at any age, regardless of the presence of comorbidities. Conclusions. Domestic drugs (51 % of the total range) dominate in the market structure. The main part (94 %) consist of monocomponent preparations. The results of the research prove the relevance of the development of new combined soft dosage forms for the treatment of herpes viral diseases, which should be produced by the Ukrainian industry and satisfy the medical and economical needs of patients. The results of the marketing analysis show that it is relevant and promising to create new combined the soft dosage forms for the treatment of herpes viral diseases.

Methodological aspects of creating a soft dosage form with the antiviral effect

“…Найбільша частка припадає на однокомпонентні препарати (94 %). Засоби у м'яких лікарських формах становлять лише 8 % [13]. Для створення лікарського препарату комплексної дії було обрано як активні фармацевтичні інгредієнти ацикловір та мірамістин.…”

Development and validation of the method for the quantitative determination of acyclovir and miramistin in a soft dosage form

“…І ПУБЛІКАЦІЙ Аналіз публікацій засвідчує перспективність застосування ацикловіру та мірамістину в терапії герпесвірусних захворювань [4]. Як доводять результати маркетингових досліджень, виробники ЛЗ для лікування герпесвірусних хвороб на фармацевтичний ринок України постачають монопрепарати (94 %) [5]. Проте відомо, що комбіновані ЛЗ уможливлюють вплив на різні ланки патогенезу захворювання.…”